An 18-year-old has died from injuries sustained in the devastating fire at Le Constellation bar in Crans-Montana, raising the final death toll to 41. The incident, which occurred during New Year's celebrations, also left over 100 injured, with many still hospitalized across Europe.
After nearly two years of near-total closure, the Rafah border crossing between Gaza and Egypt is set to reopen under a coordinated pilot operation. The move, a key element of international ceasefire efforts, will initially allow hundreds of critically ill patients and their families to seek medical care abroad.
Israel has reopened the Rafah border crossing between Gaza and Egypt for limited pedestrian movement, a move long demanded by aid agencies. However, the crucial flow of humanitarian supplies remains restricted, and the reopening follows deadly violence in the area.
The Israeli government has ordered Médecins Sans Frontières (MSF) to cease operations in Gaza by the end of February, citing the aid group's refusal to hand over details of its Palestinian staff—a move critics decry as a dangerous politicization of humanitarian aid.
Israel announces a limited, security-heavy reopening of Gaza's Rafah crossing with Egypt, allowing some medical evacuations while concerns mount over aid access and the safety of returnees.
Glaukos shares have rebounded nearly 8% in a month, yet remain down sharply over the past year. A deep dive into the numbers reveals a stark contrast: a discounted cash flow model suggests significant upside, while price-to-sales metrics paint a picture of a richly valued stock. Investors are left weighing the promise of future glaucoma innovation against current market multiples.
In an exclusive interview, Robert F. Kennedy Jr. addresses the state of his relationship with cousin Caroline Kennedy following the death of her daughter, Tatiana Schlossberg, last December. The tragedy unfolds against a backdrop of deep political rifts within America's most storied political dynasty.
Glaukos Corporation's iDose TR glaucoma therapy receives a key FDA labeling update, permitting repeat administration. While the news bolsters the company's growth narrative, analysts are divided on whether its current stock price already reflects future potential amid rich valuation metrics.
Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
Amid a steep 60% annual share price decline, investment firm Chicago Capital has significantly reduced its position in PROCEPT BioRobotics, a developer of robotic systems for urological surgery, signaling a portfolio risk reassessment.
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
After a bruising year that saw its shares tumble by a third, biotech giant CSL is back in the spotlight. We delve beyond the headline numbers, examining valuation models and market sentiment to assess if the sell-off has created a compelling entry point for long-term investors.
A devastating landslide at the Rubaya coltan mine in eastern DRC has claimed hundreds of lives, casting a harsh spotlight on the perilous conditions in artisanal mining and the complex conflict over the region's critical minerals.
Galderma Group's (SWX:GALD) shares have faced significant pressure in recent months, contrasting sharply with its strong yearly performance. This analysis delves into whether the current valuation presents a genuine entry point or reflects deeper concerns about the dermatology giant's ambitious growth narrative.
Facing softer demand and tariff volatility, Minerals Technologies (MTX) reported steady 2025 sales of $2.1B but saw margins contract. Leadership emphasized cost discipline and safety while detailing a series of expansion projects poised to drive a meaningful rebound in the coming year.
Chemical and ammunition manufacturer Olin Corporation reported fourth-quarter results that missed internal forecasts, pressured by plant disruptions, supply issues, and a sharp year-end drop in chlorine demand. Executives emphasized cash preservation and cost control while navigating what they term an extended market downturn.
Merck & Co. shifts its cancer drug development playbook, opting for targeted collaborations with Guardant Health and Eikon Therapeutics after walking away from a major acquisition. Analysts debate whether the stock's current price fully reflects its long-term pipeline potential.
The FDA's Priority Review for Vyvgart's label expansion in myasthenia gravis accelerates Argenx's growth strategy, while investors weigh the company's broader pipeline against its current valuation.
